XML 46 R32.htm IDEA: XBRL DOCUMENT
v3.24.4

Stock-Based Compensation (Tables) | 9 Months Ended | 12 Months Ended
--- | --- | ---
Sep. 30, 2024 | Dec. 31, 2023
Stock-Based Compensation [Abstract] |  |
Schedule of Grant-Date Fair Value of Stock Options Granted | The following table presents the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted during the three and nine months ended September 30, 2024 and 2023:
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Exercise price |  | $ | 1.00 – 1.12 |  |  | $ | 1.35 – 1.35 |  |  | $ | 1.00 – 1.12 |  |  | $ | 1.35 – 1.84 |
Risk-free interest rate |  |  | 5.2 – 5.2 | % |  |  | 4.8 – 4.8 | % |  |  | 5.2 – 5.2 | % |  |  | 4.7 – 4.8 | %
Expected volatility |  |  | 93.2 – 104.6 | % |  |  | 134.5 – 134.5 | % |  |  | 93.2 – 104.6 | % |  |  | 122.2 – 136.9 | %
Expected dividend yield |  |  | 0 | % |  |  | 0 | % |  |  | 0 | % |  |  | 0 | %
Expected life of options (in years) |  |  | 5.0 |  |  |  | 5.0 |  |  |  | 5.0 |  |  |  | 5.0 |
| The following table presents the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted:
|  | Year Ended |
|  | December 31, |
|  | 2023 |  |  | 2022 |
Exercise price |  |  | $0.85 – 1.84 |  |  |  | $1.67 – 2.61 |
Risk-free interest rate |  |  | 4.7 – 5.0% |  |  |  | 0.6 – 4.5% |
Expected volatility |  |  | 98 – 137% |  |  |  | 127 – 164% |
Expected dividend yield |  |  | 0% |  |  |  | 0% |
Expected life of options (in years) |  |  | 5.0 |  |  |  | 5.0 |
Schedule of Option Activity | The following table summarizes the Company’s option activity for the nine months ended September 30, 2024 (in thousands, except exercise price and contractual life data):
|  | Number Outstanding |  |  | Weighted Average Exercise Price per Share |  |  | Weighted Average Remaining Contractual Life (Years) |
Balance as of January 1, 2024 |  |  | 13,843 |  |  | $ | 2.64 |  |  |  | 3.7 |
Granted |  |  | 250 |  |  |  | 1.01 |  |  |  | 5.0 |
Exercised |  |  | - |  |  |  | - |  |  |  | - |
Forfeited |  |  | (1,724 | ) |  |  | 4.11 |  |  |  | - |
Balance as of September 30, 2024 |  |  | 12,369 |  |  | $ | 2.41 |  |  |  | 3.1 |
Vested and exercisable as of September 30, 2024 |  |  | 8,375 |  |  | $ | 2.87 |  |  |  | 2.8 |
| The following table summarizes the Company’s option activity:
Weighted Average Number of Shares (in thousands) |  | Weighted Average Exercise Price |  |  | Contractual Term (in years) |
Outstanding as of December 31, 2021 |  |  |  |  |  |  |  |  |
As previously reported |  |  | 5,197 |  |  | $ | 7.68 |  |  |  | 2.5 |
Adjustments (1) |  |  | (1,100 | ) |  |  | (2.45 | ) |  |  | 1.4 |
As restated |  |  | 4,097 |  |  |  | 5.23 |  |  |  | 3.9 |
Granted |  |  | 6,853 |  |  |  | 1.38 |  |  |  | 5.0 |
Forfeited |  |  | (1,785 | ) |  |  | 3.17 |  |  |  | - |
Outstanding as of December 31, 2022 |  |  | 9,165 |  |  |  | 3.51 |  |  |  | 4.2 |
Granted |  |  | 5,340 |  |  |  | 1.38 |  |  |  | 5.0 |
Forfeited |  |  | (662 | ) |  |  | 4.41 |  |  |  | - |
Outstanding as of December 31, 2023 |  |  | 13,843 |  |  | $ | 2.64 |  |  |  | 3.7 |
Vested as of December 31, 2022 |  |  | 6,413 |  |  | $ | 3.58 |  |  |  | 4.2 |
Vested as of December 31, 2023 |  |  | 8,803 |  |  | $ | 3.21 |  |  |  | 3.4 |
Schedule of Exercise Price Range | The following table summarizes the exercise price range as of September 30, 2024 (in thousands, except exercise price data):
Exercise Price |  |  | Outstanding Options |  |  | Exercisable Options |
$ | 0.00 – 1.00 |  |  |  | 105 |  |  |  | 10 |
$ | 1.00 – 2.00 |  |  |  | 5,348 |  |  |  | 1,794 |
$ | 2.00 – 3.00 |  |  |  | 5,845 |  |  |  | 5,500 |
$ | 3.00 – 6.00 |  |  |  | 38 |  |  |  | 38 |
$ | 6.00 – 8.00 |  |  |  | 683 |  |  |  | 683 |
$ | 8.00 – 12.00 |  |  |  | 350 |  |  |  | 350 |
|  |  |  |  | 12,369 |  |  |  | 8,375 |
| The following table summarizes the exercise price range as of December 31, 2023 (in thousands):
Exercise Price |  |  | Outstanding Options |  |  | Exercisable Options |
$ | 0.00 – 1.00 |  |  |  | 180 |  |  |  | 10 |
$ | 1.00 – 2.00 |  |  |  | 5,695 |  |  |  | 1,935 |
$ | 2.00 – 3.00 |  |  |  | 6,359 |  |  |  | 5,318 |
$ | 3.00 – 5.00 |  |  |  | 65 |  |  |  | 65 |
$ | 5.00 – 7.00 |  |  |  | 726 |  |  |  | 713 |
$ | 7.00 – 12.00 |  |  |  | 818 |  |  |  | 762 |
|  |  |  |  | 13,843 |  |  |  | 8,803 |
Schedule of Stock-Based Compensation Expense Related to Common Stock Options and Restricted Shares of Common Stock | The Company recognized stock-based compensation expense for services in lieu of cash payments to certain consultants, including expenses for both shares issued and stock option awards granted, in the following expense categories of its consolidated statements of operations (in thousands):
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Selling and marketing |  | $ | - |  |  | $ | (107 | ) |  | $ | - |  |  | $ | (174 | )
General and administrative |  |  | 2 |  |  |  | 107 |  |  |  | 21 |  |  |  | 456 |
Total stock-based compensation |  | $ | 2 |  |  | $ | - |  |  | $ | 21 |  |  | $ | 282 |
| The Company recognized stock-based compensation expense related to common stock options and restricted shares of common stock in the following expense categories of its consolidated statements of operations (in thousands):
|  | Year Ended December 31, |
|  | 2023 |  |  | 2022 |
Research and development |  |  | 2,080 |  |  |  | 509 |
Selling and marketing |  |  | (279 | ) |  |  | 494 |
General and administrative |  |  | 2,470 |  |  |  | 8,320 |
Total stock-based compensation |  | $ | 4,271 |  |  | $ | 9,323 |
Schedule of Stock-Based Compensation Expense Related to Common Stock Options and Restricted Shares of Common Stock | The Company recognized stock-based compensation expense related to common stock options and restricted shares of common stock in the following expense categories of its consolidated statements of operations (in thousands):
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
Research and development |  | $ | 562 |  |  | $ | 408 |  |  | $ | 1,761 |  |  | $ | 1,358 |
Selling and marketing |  |  | 12 |  |  |  | 85 |  |  |  | 123 |  |  |  | (351 | )
General and administrative |  |  | 189 |  |  |  | 499 |  |  |  | 796 |  |  |  | 2,103 |
Total stock-based compensation |  | $ | 763 |  |  | $ | 992 |  |  | $ | 2,680 |  |  | $ | 3,110 |

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration